Further study revealed that the crosstalk of BMFs with cancer cells induce the upregulation of PD-L1 expression in BMFs by activating the Wnt/β-catenin signaling pathway, which may be a potential therapy target to resensitizing BMF-rich tumors to aPD-L1 immunotherapy. Here, CD274 is linked to cancer.